42 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47.
BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday.
Mid-Morning Market Update: Markets Mostly Lower; ISM Services PMI Falls In June
Following the market opening Tuesday, the Dow traded down 0.62% to 34,569.49 while the NASDAQ rose 0.19% to 14,667.72. The S&P also fell, dropping 0.27% to 4,340.67.
56 Biggest Movers From Friday
Gainers
Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
T.A.T. Technologies Ltd. (NASDAQ: TATT) shares rose 53.4% to $9.09 in pre-market trading after the company announced a new MRO partnership with Honeywell.
58 Biggest Movers From Yesterday
Gainers
The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.
Mid-Afternoon Market Update: Dow Gains 100 Points; NovoCure Shares Plunge
Toward the end of trading Thursday, the Dow traded up 0.29% to 34,603 while the NASDAQ rose 0.01% to 14,504.68. The S&P also rose, gaining 0.44% to 4,316.39.
Mid-Day Market Update: Crude Oil Rises Over 2%; Aligos Therapeutics Shares Slide
Midway through trading Thursday, the Dow traded up 0.20% to 34,571.92 while the NASDAQ fell 0.24% to 14,468.72. The S&P also rose, gaining 0.24% to 4,307.60
30 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per share.
Mid-Morning Market Update: Markets Open Higher; Walgreens Posts Q3 Profit
Following the market opening Thursday, the Dow traded up 0.18% to 34,565.67 while the NASDAQ rose 0.08% to 14,515.51. The S&P also rose, gaining 0.28% to 4,309.37.
20 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434 Phase 2 clinical trial.